Cancer Care Ontario | Cancer Care Ontario

430 Results

Guidelines and Advice

First-line treatment of advanced-stage Hodgkin lymphoma

Status: Current
ID: ES 6-25

Oct 2024

Guidelines and Advice

An Endorsement of the ASTRO/ESTRO 2023 Guideline for the Treatment of Patients with Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

Status: Current
ID: GL END 7-24

Nov 2024

Guidelines and Advice

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Status: Current
ID: Guideline Endorsement C50-CIDAP-2

Nov 2024

Guidelines and Advice

Organizational Requirements for Acute Leukemia Service Providers in Ontario: Recommendations Report 2024

Status: Current
Version: 2

Dec 2024

Guidelines and Advice

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Status: Current
ID: 7-A-2022-1-17v3
Version: 3

Oct 2023

Guidelines and Advice

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Status: Current
ID: MOTAC-7

Updated

Jan 2025

Guidelines and Advice

Endometrial Cancer Molecular Testing Recommendations Report

Status: Current
Version: 1

Nov 2024

Guidelines and Advice

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Status: Current

Updated

Mar 2025

Guidelines and Advice

Ontario Cervical Screening Program: Guidance for Vaginal Vault Testing

Status: Current

Updated

Mar 2025

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Updated

Mar 2025

Guidelines and Advice

Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

Status: Current
ID: GL 17-10 v2
Version: 2

Updated

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Updated

Mar 2025

First-line treatment of advanced-stage Hodgkin lymphoma

An Endorsement of the ASTRO/ESTRO 2023 Guideline for the Treatment of Patients with Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer

An Endorsement of the 2023 European Association of Urology (EAU) -American Society of Clinical Oncology (ASCO) Guidelines on Penile Cancer

Organizational Requirements for Acute Leukemia Service Providers in Ontario: Recommendations Report 2024

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

The Use of Molecular Tools for Identifying and Guiding Treatment of Cancers of Unknown Primary

Endometrial Cancer Molecular Testing Recommendations Report

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Ontario Cervical Screening Program: Guidance for Vaginal Vault Testing

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Pages